KBTBD2: A Potential Drug Target and Biomarker (G25948)

Target Name: KBTBD2

NCBI ID: G25948

KBTBD2

KBTBD2: A Potential Drug Target and Biomarker

Kelch repeat and BTB (POZ) domain containing 2 (KBTBD2) is a protein that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The KBTBD2 protein is a key component of the endoplasmic reticulum and is involved in the regulation of protein stability and localization to the plasma membrane.

The Kelch repeat and BTB (POZ) domain containing 2 protein is composed of 284 amino acid residues and has a calculated molecular mass of 31 kDa. It is localized to the endoplasmic reticulum and is involved in the regulation of protein stability and localization to the plasma membrane. KBTBD2 is a protein that has been shown to play a role in various cellular processes, including cell signaling, protein folding, and localization to the endoplasmic reticulum.

Recent studies have identified KBTBD2 as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, KBTBD2 has been shown to be involved in the regulation of cancer cell survival and has been identified as a potential drug target for cancer therapy. Additionally, KBTBD2 has been shown to be involved in the regulation of neurodegenerative diseases, including Alzheimer's disease, and has been identified as a potential biomarker for neurodegenerative diseases.

In addition to its potential as a drug target, KBTBD2 has also been shown to be a potential biomarker for various diseases. For example, KBTBD2 has been shown to be involved in the regulation of inflammation and has been identified as a potential biomarker for autoimmune disorders. Additionally, KBTBD2 has been shown to be involved in the regulation of cell signaling and has been identified as a potential biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

KBTBD2 has also been shown to play a role in the regulation of protein stability and localization to the plasma membrane. This suggests that KBTBD2 may be involved in the regulation of various cellular processes, including protein folding, localization to the endoplasmic reticulum, and stability.

In conclusion, KBTBD2 is a protein that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its role in the regulation of protein stability and localization to the plasma membrane suggests that KBTBD2 may be involved in the regulation of various cellular processes, including protein folding, localization to the endoplasmic reticulum, and stability. Further research is needed to fully understand the role of KBTBD2 as a potential drug target and biomarker for various diseases.

Protein Name: Kelch Repeat And BTB Domain Containing 2

Functions: Substrate-specific adapter of a BCR (BTB-CUL3-RBX1) E3 ubiquitin ligase complex that acts as a regulator of the insulin signaling pathway, modulating insulin sensitivity by limiting PIK3R1/p85alpha abundance in adipocytes. Targets PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase (PI3K), for 'Lys-48'-linked polyubiquitination and proteasome-mediated degradation

The "KBTBD2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KBTBD2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets